Ansofaxine Hydrochloride inhibits hepatocellular carcinoma growth and enhances targeted therapy through the EGFR/MAPK pathway
Our study suggests that Ansofaxine Hydrochloride has anti-HCC and immunomodulatory effects, with the EGFR/MAPK pathway as a potential key mechanism of action.
Authors
- Meifeng Chen (ORCID: https://orcid.org/0000-0002-7170-0843)
- Qiang Tao (ORCID: https://orcid.org/0000-0002-5731-9560)
- Shutian Mo (ORCID: https://orcid.org/0000-0001-9385-0757)
- Guangquan Zhang (ORCID: https://orcid.org/0000-0003-3960-0583)
- Yongfei He (ORCID: https://orcid.org/0000-0001-8813-1416)
- Jicai Wang (ORCID: https://orcid.org/0000-0001-7980-4412)
- Xianjie Shi (ORCID: https://orcid.org/0000-0001-7712-2258)
- Qiang Gao (ORCID: https://orcid.org/0000-0001-9880-4944)
- Hang Zhai
- Chuangye Han
- Shengjie Hong
Institutions
- Sun Yat-sen University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Eighth Affiliated Hospital of Sun Yat-sen University
- Inner Mongolia Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fonc.2025.1523570
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00